Finance News World

(Albany, New York) – October 09, 2026: DelveInsight’s “IgA Nephropathy Market Insights, Epidemiology, and Market Forecast-2036″ report offers an in-depth understanding of the IgA Nephropathy, historical and forecasted epidemiology as well as the IgA Nephropathy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the IgA Nephropathy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; IgA Nephropathy Market Forecast

Some of the key facts of the IgA Nephropathy Market Report:

• The IgA Nephropathy market size was valued approximately USD 730 million in 2024 and is anticipated to grow with a significant CAGR during the study period (2022-2036).

• In October 2026, Vera is scheduled to present the final ORIGIN 3 efficacy analysis for Trutakna at ASN Kidney Week 2026 on October 22, alongside interim data from the Phase II PIONEER trial evaluating atacicept in IgAN and primary membranous nephropathy.

• In September 2026, Alebund Pharmaceuticals received clearance from the US Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for AP308, a first-in-class engineered recombinant IgA protease being developed to treat IgA nephropathy. The IND clearance enables the program to advance from preclinical research into clinical development, with the company planning to initiate clinical studies in the near future. AP308 is designed to directly cleave and eliminate pathogenic IgA and IgA-containing immune complexes implicated in the development and progression of IgA nephropathy.

• In August 2026, Otsuka Pharmaceutical’s Voyxact is no longer the only IgA nephropathy therapy demonstrating the potential to slow the decline in kidney function. Vera Therapeutics’ Trutakna, which recently received accelerated FDA approval, has also shown encouraging improvements in kidney function, with analysts highlighting its potential to stabilize disease progression. Otsuka had previously presented data suggesting that Voyxact could offer a distinct advantage by slowing the deterioration of kidney function in patients with IgA nephropathy. However, the approval of Trutakna may challenge this differentiation, as the newly approved therapy has demonstrated similarly promising effects on kidney function, according to the FDA.

• In May 2025, Otsuka Pharmaceuticals recently announced that the FDA has accepted the Biologics License Application (BLA) for sibeprenlimab, an APRIL (a proliferation-inducing ligand) inhibitor being developed for the treatment of immunoglobulin A nephropathy (IgAN). This follows the FDA’s 2024 Breakthrough Therapy Designation granted to sibeprenlimab for the same condition. The BLA submission is backed by data from the Phase III VISIONARY trial. According to GlobalData, the priority review underscores sibeprenlimab’s potential advantages over current therapies and reinforces its promise as a treatment for the complex nature of IgAN. If approved, it would become the first disease-modifying option addressing both clinical and practical aspects of managing IgAN.

• In March 2025, Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) has announced topline findings from Part 2 of its Phase 1/2 clinical trial evaluating ARO-C3, an investigational RNA interference (RNAi) therapy aimed at lowering liver production of complement component 3 (C3) to potentially treat multiple complement-mediated disorders.

• In 2024, the market size for IgA Nephropathy (IgAN) in the US was around USD 455 million and is expected to grow with the introduction of emerging therapies.

• The total market size for the EU4 and the UK was estimated at around USD 150 million in 2024, representing nearly 21% of the overall market revenue for the 7MM, with growth expected by 2036.

• In 2024, Germany led the IgAN market among the EU4 and the UK with approximately USD 45 million in revenue, followed by France at around USD 35 million and Italy at nearly USD 30 million.

• In 2024, Japan’s IgAN market size was estimated at around USD 125 million, with expectations of growth throughout the forecast period from 2025 to 2036.

• DelveInsight estimates that around 415,000 prevalent cases of IgA Nephropathy (IgAN) were reported across the 7MM in 2024. These diagnosed cases are expected to grow at a CAGR of 0.6% by 2036.

• In 2024, the United States reported approximately 133,000 diagnosed prevalent cases of IgA Nephropathy (IgAN), with numbers expected to rise by 2036.

• In 2024, Germany had the highest number of diagnosed prevalent cases of IgA Nephropathy (IgAN) among the EU4 and the UK, with approximately 30,000 cases, while Spain had the lowest, with around 5,000 cases.

• In 2024, Japan reported the highest number of diagnosed prevalent cases of IgA Nephropathy (IgAN) among the 7MM, with nearly 175,000 cases, and this number is projected to increase by 2036.

• In 2024, France reported around 16,000 diagnosed prevalent cases of IgA Nephropathy (IgAN) in males and 8,000 in females, with both numbers anticipated to increase by 2036.

• Key IgA Nephropathy Companies: Travere Therapeutics, Asahi Kasei (Calliditas Therapeutics), Vertex Pharmaceuticals, Vera Therapeutics, Visterra, Chinook Therapeutics, Novartis, IgA proteases Selecta Biosciences, Shanghai Alebund Pharmaceuticals, Rohto Pharmaceutical, Wuhan Createrna Science and Technology, Guangdong Hengrui Pharmaceutical, LRx Ionis Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Travere Therapeutics, and others

• Key IgA Nephropathy Therapies: VANRAFIA (atrasentan), FILSPARI (sparsentan), TARPEYO/KINPEYGO (budesonide), Povetacicept (ALPN-303), Atacicept, Zigakibart (FUB523), Sibeprenlimab, Atrasentan, LNP023, Research programme, AP 305, ADR-001, MY 008, SHR-2010, IONIS FB, HR19042, Sparsentan, HR19042, and others

• The IgA Nephropathy epidemiology based on gender analyzed that IgAN is more prominent in males in comparison to females. Prevalence of IgAN occurs in men around two times more than females worldwide.

• The IgA Nephropathy market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage IgA Nephropathy pipeline products will significantly revolutionize the IgA Nephropathy market dynamics.

IgA Nephropathy Overview

IgA nephropathy, also known as Berger’s disease, is a kidney disorder characterized by the buildup of the antibody immunoglobulin A (IgA) in the kidneys. This buildup can lead to inflammation and damage to the tiny filters in the kidneys called glomeruli. IgA nephropathy is one of the most common forms of glomerulonephritis, which is inflammation of the glomeruli.

Get a Free sample for the IgA Nephropathy Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/iga-nephropathy-igan-market

IgA Nephropathy Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

IgA Nephropathy Epidemiology Segmentation:

The IgA Nephropathy market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM segmented into:

• Total Prevalence of IgA Nephropathy

• Prevalent Cases of IgA Nephropathy by severity

• Gender-specific Prevalence of IgA Nephropathy

• Diagnosed Cases of Episodic and Chronic IgA Nephropathy

Download the report to understand which factors are driving IgA Nephropathy epidemiology trends @ IgA Nephropathy Epidemiology Forecast

IgA Nephropathy Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the IgA Nephropathy market or expected to get launched during the study period. The analysis covers IgA Nephropathy market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the IgA Nephropathy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

IgA Nephropathy Therapies and Key Companies

• VANRAFIA (atrasentan): Novartis

• FILSPARI (sparsentan): Travere Therapeutics

• TARPEYO/KINPEYGO (budesonide): Asahi Kasei (Calliditas Therapeutics)

• Povetacicept (ALPN-303): Vertex Pharmaceuticals

• Atacicept: Vera Therapeutics

• Zigakibart (FUB523): Novartis

• Sibeprenlimab: Visterra

• Atrasentan: Chinook Therapeutics

• LNP023: Novartis Pharmaceuticals

• Research programme: IgA proteases Selecta Biosciences

• AP 305: Shanghai Alebund Pharmaceuticals

• ADR-001: Rohto Pharmaceutical

• MY 008: Wuhan Createrna Science and Technology

• SHR-2010: Guangdong Hengrui Pharmaceutical

• IONIS FB: LRx Ionis Pharmaceuticals

• HR19042: Jiangsu HengRui Medicine Co., Ltd.

• Sparsentan: Travere Therapeutics

• HR19042: Jiangsu HengRui Medicine Co., Ltd.

Discover more about therapies set to grab major IgA Nephropathy market share @ IgA Nephropathy Treatment Landscape

IgA Nephropathy Market Drivers

• Increasing disease awareness and diagnosis: Greater recognition of IgA nephropathy and improved diagnostic practices are supporting earlier identification and treatment.

• Growing demand for targeted therapies: The emergence of disease-specific treatments targeting immune and renal pathways is creating significant market opportunities.

• High unmet need: Limited effective treatment options for patients at risk of disease progression continue to drive research and therapeutic innovation.

• Advancements in clinical development: Increasing investment in novel therapies, including complement inhibitors and targeted immunomodulators, is expanding the treatment pipeline.

• Rising risk of kidney disease progression: The potential progression of IgA nephropathy to chronic kidney disease and end-stage kidney disease is increasing the need for therapies that can preserve renal function.

IgA Nephropathy Market Barriers

• Limited disease awareness: Underdiagnosis and delayed diagnosis, particularly in regions with limited access to nephrology services, can restrict market growth.

• Biopsy-dependent diagnosis: Kidney biopsy is generally required for definitive diagnosis, which can be invasive and may limit diagnosis in some patients.

• High cost of novel therapies: Premium pricing of newly approved targeted treatments may create affordability and reimbursement challenges.

• Disease heterogeneity: Differences in disease severity, progression risk, and treatment response make patient identification and treatment selection challenging.

• Safety and long-term efficacy concerns: Uncertainty around the long-term safety, durability, and real-world effectiveness of emerging therapies may influence physician adoption and payer acceptance.

Scope of the IgA Nephropathy Market Report

• Study Period: 2022–2036

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key IgA Nephropathy Companies: Travere Therapeutics, Asahi Kasei (Calliditas Therapeutics), Vertex Pharmaceuticals, Vera Therapeutics, Visterra, Chinook Therapeutics, Novartis, IgA proteases Selecta Biosciences, Shanghai Alebund Pharmaceuticals, Rohto Pharmaceutical, Wuhan Createrna Science and Technology, Guangdong Hengrui Pharmaceutical, LRx Ionis Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Travere Therapeutics, and others

• Key IgA Nephropathy Therapies: VANRAFIA (atrasentan), FILSPARI (sparsentan), TARPEYO/KINPEYGO (budesonide), Povetacicept (ALPN-303), Atacicept, Zigakibart (FUB523), Sibeprenlimab, Atrasentan, LNP023, Research programme, AP 305, ADR-001, MY 008, SHR-2010, IONIS FB, HR19042, Sparsentan, HR19042, and others

• IgA Nephropathy Therapeutic Assessment: IgA Nephropathy current marketed and IgA Nephropathy emerging therapies

• IgA Nephropathy Market Dynamics: IgA Nephropathy market drivers and IgA Nephropathy market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• IgA Nephropathy Unmet Needs, KOL’s views, Analyst’s views, IgA Nephropathy Market Access and Reimbursement

To know more about IgA Nephropathy companies working in the treatment market, visit @ IgA Nephropathy Clinical Trials and Therapeutic Assessment

Table of Contents

1. IgA Nephropathy Market Report Introduction

2. Executive Summary for IgA Nephropathy

3. SWOT analysis of IgA Nephropathy

4. IgA Nephropathy Patient Share (%) Overview at a Glance

5. IgA Nephropathy Market Overview at a Glance

6. IgA Nephropathy Disease Background and Overview

7. IgA Nephropathy Epidemiology and Patient Population

8. Country-Specific Patient Population of IgA Nephropathy

9. IgA Nephropathy Current Treatment and Medical Practices

10. IgA Nephropathy Unmet Needs

11. IgA Nephropathy Emerging Therapies

12. IgA Nephropathy Market Outlook

13. Country-Wise IgA Nephropathy Market Analysis (2022–2036)

14. IgA Nephropathy Market Access and Reimbursement of Therapies

15. IgA Nephropathy Market Drivers

16. IgA Nephropathy Market Barriers

17. IgA Nephropathy Appendix

18. IgA Nephropathy Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/